We are live on ! Find out more
OCA

Octagon Capital Advisors Portfolio holdings

AUM $1.11B
1-Year Est. Return 866.76%
This Fund
S&P 500
This Quarter Est. Return
+25.07%
1 Year Est. Return
+866.76%
3 Year Est. Return
+2,969.39%
5 Year Est. Return
+5,038.91%
10 Year Est. Return
–
AUM
$642M
AUM Growth
+$62.8M
Cap. Flow
+$62.8M
Cap. Flow %
9.78%
Top 10 Hldgs %
78.63%
Holding
44
New
9
Increased
4
Reduced
7
Closed
12

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$34.8M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$34.2M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$27.3M
4
VRDN icon
Viridian Therapeutics
VRDN
+$19M
5
VRNA
Verona Pharma
VRNA
+$15.2M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$38.6M
2
HRMY icon
Harmony Biosciences
HRMY
+$10.8M
3
ASND icon
Ascendis Pharma A/S
ASND
+$8.62M
4
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$7.76M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$7.47M

Sector Composition

Rank Sector Weight
1 Healthcare 97.42%
2 Miscellaneous 2.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
1
DELISTED
Apellis Pharmaceuticals
APLS
$163M 25.44%
3,160,000
+656,941
+26% +$34.8M
KDNY
2
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$66.9M 10.41%
2,551,703
– –
VRNA
3
DELISTED
Verona Pharma
VRNA
$64.5M 10.04%
2,468,000
+1,143,132
+86% +$15.2M
RCUS icon
4
Arcus Biosciences
RCUS
$3.78B
$51.3M 7.99%
2,482,700
-185,616
-7% -$5.11M
MRTX
5
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$34M 5.29%
750,000
+529,000
+239% +$34.2M
CLDX icon
6
Celldex Therapeutics
CLDX
$3.12B
$33.9M 5.28%
761,398
– –
ISEE
7
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$27.4M 4.26%
+1,278,000
New +$27.3M
VRDN icon
8
Viridian Therapeutics
VRDN
$2.6B
$24.1M 3.75%
+824,200
New +$19M
TNDM icon
9
Tandem Diabetes Care
TNDM
$1.38B
$21.3M 3.32%
474,929
– –
JBIO
10
Jade Biosciences
JBIO
$1.27B
$18.2M 2.84%
+17,763
New +$12.9M
XBI icon
11
State Street SPDR S&P Biotech ETF
XBI
$11.4B
$16.6M 2.58%
199,417
-43,983
-18% -$3.56M
VERA icon
12
Vera Therapeutics
VERA
$2.59B
$12.9M 2%
665,156
+131,892
+25% +$2.39M
ITCI
13
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$11.7M 1.82%
220,953
– –
CBAY
14
DELISTED
Cymabay Therapeutics
CBAY
$11.7M 1.82%
+1,859,200
New +$7.07M
FDMT icon
15
4D Molecular Therapeutics
FDMT
$827M
$11.1M 1.73%
499,996
– –
ALPN
16
DELISTED
Alpine Immune Sciences Inc
ALPN
$9M 1.4%
1,225,000
– –
ITOS
17
DELISTED
iTeos Therapeutics
ITOS
$8.69M 1.35%
+445,000
New +$8.7M
VKTX icon
18
Viking Therapeutics
VKTX
$4.07B
$8.18M 1.27%
+870,500
New +$3.89M
RNAM
19
DELISTED
Avidity Biosciences
RNAM
$7.2M 1.12%
324,629
-55,000
-14% -$820K
BBIO icon
20
BridgeBio Pharma
BBIO
$14.6B
$7.12M 1.11%
933,743
– –
STOK icon
21
Stoke Therapeutics
STOK
$1.92B
$7.05M 1.1%
763,456
– –
XLO icon
22
Xilio Therapeutics
XLO
$59.2M
$6.52M 1.02%
173,214
– –
ETNB
23
DELISTED
89bio
ETNB
$4.84M 0.75%
+380,000
New +$3.42M
GOSS icon
24
Gossamer Bio
GOSS
$85.7M
$4.25M 0.66%
1,958,069
-87,373
-4% -$719K
MIRM icon
25
Mirum Pharmaceuticals
MIRM
$6.15B
$1.95M 0.3%
100,000
– –
1
2

Similar funds

OBWG
Onyx Bridge Wealth Group Tarrytown, New York $1.11B AUM 24.65% 1-Year Est. Return
FMI
Frec Markets Inc San Francisco, California $1.11B AUM
JWM
JGP Wealth Management Bend, Oregon $1.11B AUM 35.22% 1-Year Est. Return
MSA
Mason Street Advisors Milwaukee, Wisconsin $1.11B AUM 12.31% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
AF
Arrow Financial Glens Falls, New York $1.12B AUM 24.16% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.11B AUM 38.73% 1-Year Est. Return
VFM
Viking Fund Management Minot, North Dakota $1.12B AUM 44.65% 1-Year Est. Return

Octagon Capital Advisors's Q4 2022 Portfolio in Review

As of Q4 2022, Octagon Capital Advisors held 44 positions worth $642M, up 11% from $579M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Octagon Capital Advisors deployed $62.8M of net new capital in Q4 2022, opening 9 new positions and adding to 4 existing holdings. Its largest new stake was IVERIC bio, Inc. Common Stock: 1,278,000 shares worth $27.4M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Arcus Biosciences, an estimated $5.11M trimmed.

  • Octagon Capital Advisors's largest Q4 2022 buy was IVERIC bio, Inc. Common Stock: 1,278,000 shares worth $27.4M.
  • Octagon Capital Advisors added most to Apellis Pharmaceuticals in Q4 2022, an estimated $34.8M increase.
  • Octagon Capital Advisors's biggest Q4 2022 reduction was Arcus Biosciences, cutting an estimated $5.11M.
  • Octagon Capital Advisors fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022, selling an estimated $38.6M.
  • Octagon Capital Advisors's ten largest holdings make up 79% of its $642M portfolio in Q4 2022.
  • Octagon Capital Advisors opened 9 new positions and closed 12 in Q4 2022.
  • Octagon Capital Advisors's portfolio value rose 11% quarter-over-quarter to $642M.

Based on Octagon Capital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.